Center for Advanced Multi-Omic Characterization of Cancer

癌症高级多组学表征中心

• 批准号: 10755578
• 负责人: Tao Liu
• 金额: $ 51.68万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10755578
• 关键词: Acceleration; Acute Myelocytic Leukemia; Acute T Cell Leukemia; Cells; Center for Translational Science Activities; Child; Childhood; Childhood Leukemia; Clinical; Clinical Trials; Collaborations; Colorectal Cancer; Communities; Country; Data; Data Analyses; Defect; Disease; Funding; Future; Genome; Genomics; Immunotherapy; Investments; Label; Laboratories; Liquid Chromatography; Malignant Childhood Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Mass Spectrum Analysis; Molecular; National Cancer Institute; Pacific Northwest; Pathway interactions; Pediatric Research; Phenotype; Phosphorylation; Post-Translational Protein Processing; Proteins; Proteome; Proteomics; Relapse; Resistance; Resources; Sampling; Signal Pathway; Standardization; Toxic effect; United States National Institutes of Health; anticancer research; cancer type; driver mutation; genome analysis; high risk; insight; instrumentation; leukemia; malignant breast neoplasm; multiple omics; novel; novel therapeutics; open source; precision oncology; programs; proteogenomics; tandem mass spectrometry; targeted treatment; tumor

PROJECT SUMMARY The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Launched in 2011, CPTAC pioneered the integrated proteogenomic analysis of colorectal, breast and ovarian cancer to reveal new insights into these cancer types, such as identification of proteomic-centric subtypes, prioritization of driver mutations by correlative analysis of copy number alterations and protein abundance, and understanding cancer-relevant pathways through post- translational modifications. In this project, CPTAC will collaborate with the NIH Common Fund Gabriella Miller Kids First Pediatric Research Program (Kids First) to comprehensively characterize pediatric leukemia samples (such as T-cell acute lymphoblastic leukemia, T-ALL, and acute myeloid leukemia, AML) using mass spectrometry-based proteomics. This project will fully integrate proteogenomic information of such leukemia samples to capture and replicate specific cancer phenotype, better understand the interconnection of cancer pathways, identify novel protein targets for targeted therapies and immunotherapies, and to stimulate future pediatric cancer research and precision oncology. The PNNL PCC will perform comprehensive, integrated global proteome and phosphoproteome analyses of a total of 272 pediatric leukemia samples provided by the Kids First collaborators in various forms (such as cell pellets and surfaceome samples), using state-of-the-art liquid chromatography-tandem mass spectrometry instrumentation, highly multiplexed isobaric mass-tag labeling (TMT 18-plex), and integrated sample workflows. The resulting molecular data will become a community resource available at CAVATICA.

项目摘要 美国国家癌症研究所的临床蛋白质组肿瘤分析联盟（CPTAC）是一个全国性的努力， 通过大规模蛋白质组的应用加速对癌症分子基础的理解 和基因组分析，或蛋白质基因组学。CPTAC成立于2011年，开创了整合蛋白质基因组学 分析结直肠癌、乳腺癌和卵巢癌，以揭示对这些癌症类型的新见解， 鉴定蛋白质组学中心亚型，通过拷贝相关性分析确定驱动突变的优先级 数量变化和蛋白质丰度，并通过后 翻译修饰 在这个项目中，CPTAC将与美国国立卫生研究院共同基金加布里埃拉米勒儿童第一儿科合作 研究计划（儿童第一），以全面表征儿童白血病样本（如T细胞 急性淋巴细胞白血病，T-ALL和急性髓细胞白血病，AML）使用基于质谱的 蛋白质组学该项目将充分整合此类白血病样本的蛋白基因组信息， 复制特定的癌症表型，更好地了解癌症途径的相互联系， 用于靶向治疗和免疫治疗的蛋白质靶点，并刺激未来的儿科癌症研究 和精准肿瘤学 PNNL PCC将进行全面的，综合的全球蛋白质组和磷酸化蛋白质组分析， 儿童第一合作者以各种形式（如细胞移植）提供了总共272份儿童白血病样本。 颗粒和表面样品），使用最先进的液相色谱-串联质谱法 仪器、高度多重同量异位素质量标签标记（TMT 18-plex）和整合样品 工作流程。由此产生的分子数据将成为CAVATICA可用的社区资源。